Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) – 2021

MARKET OUTLOOK

For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.

Chronic inducible urticaria (CIndU) encompasses various chronic urticaria subtypes caused by specific triggers. CIndU appears to be more resistant than chronic spontaneous urticaria (CSU) to standard doses of antihistamines, although claims data analysis reveals positive trends among the more-recent second-generation antihistamines Clarinex and Claritin. Vistaril and montelukast are also key drugs in the CIndU therapy market, and both are often used in combination therapy. Indeed, current treatment guidelines recommend the use of leukotriene antagonists (i.e., montelukast) as add-on treatment. Biologics (e.g., TNF inhibitors) are used mainly as later-line therapy for CIndU, but because no biologics have been approved for the indication, they must be used off-label. Thus, more-effective drugs that are approved for CIndU are needed.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CIndU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CIndU patients?
  • How have second-generation antihistamines, TNF inhibitors, and Roche / Novartis’s Xolair been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of CIndU patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of CIndU patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Roche, Novartis, Sanofi, Regeneron, Abbvie, Janssen, Amgen, UCB, Pfizer, Merck, Schering-Plough

Key drugs: Allegra, Zyrtec, Benadryl, montelukast, nifedipine, Silenor, Xolair, Remicade, Enbrel, Cimzia, Simponi, Dupixent

Table of contents

  • Urticaria - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Inducible Urticaria (US) - 2021
    • Treatment Algorithms CDA Chronic Inducible Urticaria US March 2021
    • Treatment Algorithms CDA Chronic Inducible Urticaria US 2021 Dashboard